Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Investors Business Daily

Is ResMed Stock Outperforming the Nasdaq?

ResMed has outpaced the broader Nasdaq Composite index over the past year, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

ResMed Stock: Is Wall Street Bullish or Bearish?

Although ResMed has outperformed relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Fabric face mask to help apnoea sufferers rest easy

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had been dreaming about for a decade.

AAP

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year

ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

Stocks Showing Market Leadership: ResMed Earns 92 RS Rating

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

S&P 500 Giant Leads 5 Stocks Near Buy Points

S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

ResMed Breaks Out As GLP-1 Drugs And Big Tech Help Drive A Quarterly Beat

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries.

Investors Business Daily

ResMed's Q1 2025 Earnings: What to Expect

ResMed is scheduled to report its first-quarter earnings later this month, and analysts project a double-digit rise in its bottom line.

Barchart

Is ResMed Stock Outperforming the S&P 500?

ResMed has recently outperformed the S&P 500, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Three stocks to note before the Fed rate cut decision

Here are the stocks making the biggest market moves.

The Street

ResMed Stock: Analyst Estimates & Ratings

Despite ResMed’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Weight-loss drugs not lights out for ResMed: CEO

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

AAP

Five Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.

The Street

Key healthcare product maker files for Chapter 11 bankruptcy

The Pleasanton, Calif., medical device maker seeks to reorganize and eliminate $27 million in prepetition secured obligations.

Barchart

After Blowout Earnings, This Dividend Stock Still Looks Cheap

Despite its remarkable post-earnings rally, here's a dividend stock that still carries a bargain tag.

Investors Business Daily

Surging Alphabet Stock Leads Broad-Based Tech Rally; Nvidia Makes Bullish Move

The Nasdaq composite rallied sharply in the stock market today, helped by strong earnings reports from Microsoft and Google-parent Alphabet.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed

ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.

Investors Business Daily

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

Investors Business Daily

ResMed Surges And Retakes A Key Line As The Battle With Weight-Loss Drugs Rages

ResMed reported a strong December-quarter beat, an analyst said Thursday as RMD stock surged, retaking its 200-day moving average.

Top News

FDA deems ResMed's respiratory device recall as most severe

Learn about the recent recall of ResMed's respiratory devices by the US FDA, deemed as the most serious. Find out more about the implications and what acti...

Investors Business Daily

Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge

Sleep-apnea device maker ResMed broke out after earnings, continuing its accelerating growth pace.

AAP

Australians losing sleep over cost of living crisis

Australians should take sleep seriously as a survey marking World Sleep Day sheds light on the impact of financial pressures, experts say.

1 2

People

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.